VJHemOnc is committed to improving our service to you

COMy 2020 | The evolving role of IMiDs

VJHemOnc is committed to improving our service to you

Xavier Leleu

Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the importance of immunomodulatory imide drugs (IMiDs) in multiple myeloma treatment. Offsprings of thalidomide, such as lenalidomide and pomalidomide, are very effective treatments for transplant and non-transplant eligible patients. Lenalidomide is one of the best foundations for drug combinations; however, there are still areas for improvement. Some patients treated with lenalidomide become refractory. Dr Leleu also discusses CC-92480 and iberdomide. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter